Hualan Biological Engineering Inc
SZSE:002007

Watchlist Manager
Hualan Biological Engineering Inc Logo
Hualan Biological Engineering Inc
SZSE:002007
Watchlist
Price: 17.4 CNY -2.36% Market Closed
Market Cap: 31.7B CNY
Have any thoughts about
Hualan Biological Engineering Inc?
Write Note

Hualan Biological Engineering Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hualan Biological Engineering Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Hualan Biological Engineering Inc
SZSE:002007
Additional Paid In Capital
ÂĄ1.5B
CAGR 3-Years
142%
CAGR 5-Years
25%
CAGR 10-Years
15%
Beigene Ltd
HKEX:6160
Additional Paid In Capital
ÂĄ81.4B
CAGR 3-Years
15%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Additional Paid In Capital
ÂĄ27.5B
CAGR 3-Years
7%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Additional Paid In Capital
ÂĄ3.3B
CAGR 3-Years
95%
CAGR 5-Years
81%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Additional Paid In Capital
ÂĄ3.5B
CAGR 3-Years
-1%
CAGR 5-Years
90%
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Engineering Inc
Glance View

Market Cap
31.8B CNY
Industry
Biotechnology

Hualan Biological Engineering Inc., nestled in the heart of China, operates at the crossroads of innovation and health, focusing primarily on the production of vaccines and blood products. The company is at the forefront of a critical industry, ensuring the creation of products that play a pivotal role in maintaining public health. With a dedicated pursuit of scientific excellence, Hualan develops vaccines that protect against contagious diseases and specializes in plasma-derived therapeutics that have become a backbone in treating a variety of conditions requiring immune support or clotting factors. This dual focus not only showcases their expertise but also broadens their commercial portfolio, tapping into markets where demand is continually rising. Revenue streams for Hualan Biological are primarily driven by their deep penetration into domestic markets, where there is a growing emphasis on healthcare innovation and quality assurance. The company capitalizes on its research and development capabilities, which have enabled it to secure a strong pipeline of products and stay ahead in a competitive landscape. By leveraging its robust distribution network and quality manufacturing processes, Hualan ensures that its products reach hospitals and health institutions rapidly. This strategic orchestration of science and logistics allows Hualan not only to generate substantial revenues but also to reinforce its reputation as a leader within China's biopharmaceutical sector, ensuring it remains a vital contributor to public health initiatives.

Intrinsic Value
25.39 CNY
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Hualan Biological Engineering Inc's Additional Paid In Capital?
Additional Paid In Capital
1.5B CNY

Based on the financial report for Sep 30, 2024, Hualan Biological Engineering Inc's Additional Paid In Capital amounts to 1.5B CNY.

What is Hualan Biological Engineering Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
15%

Over the last year, the Additional Paid In Capital growth was 4%. The average annual Additional Paid In Capital growth rates for Hualan Biological Engineering Inc have been 142% over the past three years , 25% over the past five years , and 15% over the past ten years .

Back to Top